Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 31

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 31
---
, we have obtained our rights to our therapeutic candidates through in-license agreements
entered into with biotechnology companies that invent and own or jointly own with us the intellectual property underlying our candidates.
There is no assurance that such in-licenses or rights will not be terminated or expire due to a material breach of the agreements, such
as a failure on our part to achieve certain progress milestones set forth in the terms of the in-licenses or due to the loss of the rights
to the underlying intellectual property by any of our licensors. There is no assurance that we will be able to renew or renegotiate an
in-licensing agreement on acceptable terms if and when the agreement terminates. We cannot guarantee that any in-license is enforceable
or will not be terminated or converted into a non-exclusive license in the future. The termination of any in-license or our inability
to enforce our rights under any in-license would materially and adversely affect our ability to commercialize certain of our therapeutic
candidates.

We currently have in-licensing agreements relating to our therapeutic
candidates that are in development or are being commercialized. In 2012, we in-licensed the rights to motixafortide under a license agreement
from Biokine. Under the license agreement for motixafortide, we are obligated to make commercially reasonable, good faith efforts to sublicense
or commercialize motixafortide for fair consideration. In 2007, we in-licensed the rights to BL-5010 under a license agreement with IPC.
Under the BL-5010 license agreement, we are obligated to use commercially reasonable efforts to develop the licensed technology in accordance
with a specified development plan, including meeting certain specified diligence goals.

19

Each of the foregoing in-licensing agreements, or the obligation
to pay royalties thereunder, will generally remain in effect until the expiration, under the applicable agreement, of all the licensing,
royalty and sublicense revenue obligations to the applicable licensors, determined on a product-by-product and country-by-country basis.
We may terminate the motixafortide in-licensing agreement upon 90 days’ prior written notice to Biokine. We may terminate the BL-5010
in-licensing agreement upon 30 days’ prior written notice to IPC.

Any party to any of the foregoing in-licensing agreements may terminate
the respective agreement for material breach by the other party if the breaching party is unable to cure the breach within an agreed-upon
period, generally 30 days to 90 days